The Serum Institute of India (SII) is soon awaiting emergency use authorization from the WHO for the Oxford University / AstraZeneca coronavirus vaccine, which it is producing for middle-income countries and weak, its managing director said.
The World Health Organization (WHO) listed Pfizer and BioNTech’s Covid-19 vaccine for emergency use on December 31, as it sought to speed up vaccination in the developing world, which is in high demand. delay in western countries.
“The WHO Emergency Use Permit should be available and arrive within the next week or two, hopefully, because we have submitted everything,” Adar Poonawalla said of the AstraZeneca / Oxford vaccine during the Reuters Next conference.
Poonawalla said that SII, the world’s largest vaccine maker, was trying to start supplying the WHO-backed COVAX initiative by the end of January. It sells each dose for $ 3 for low-income countries and a “slightly higher” price for others.
Some 189 countries have joined the program, which was established to ensure equitable distribution of vaccines.
After sending around 20 million doses for the initiative in February, SII will increase that figure to 50 million per month from around April, while simultaneously selling 30 to 40 million doses each month to India, added. Poonawalla Thursday.
SII has already sold 11 million doses to the government, which is due to start a mass vaccination campaign on Saturday.
Poonawalla said SII will start stockpiling “over 40 to 50 million doses per month” of the coronavirus vaccine candidate Novavax from around April.
He said his family business, which was founded by his father Cyrus Poonawalla in 1966, is well positioned to distribute 1 billion doses of vaccine this year, with COVAX having the ability to purchase 450 million each of AstraZeneca and Novavax vaccines. .
Besides Brazil and Bangladesh, which are expected to source AstraZeneca from SII soon, Poonawalla said the Pune-based company has also been approached by Morocco, South Africa and Saudi Arabia.
As demand for vaccines grows, a so-called special-purpose vehicle housing products related to the IBS pandemic is now expected to be valued at between $ 12 billion and $ 13 billion, the SII CEO added.
“We are in a unique position to be able to manufacture so many different vaccines at an enormous volume and capacity. For an investor who has a valuation of $ 12 billion to $ 13 billion, this will be a fantastic deal, which leaves a lot of advantages. “
AstraZeneca’s Covid-19 vaccine has been approved for emergency supply in the UK.
The UK Medicines and Health Products Regulatory Agency (MHRA) has authorized the emergency supply of the Covid-19 AstraZeneca vaccine for the active immunization of people 18 years of age or older. The authorization recommends two doses administered at an interval of between four and 12 weeks. This treatment regimen has been shown to be safe and effective in preventing symptomatic Covid-19, without severe cases or hospitalization more than 14 days after the second dose.